<DOC>
	<DOC>NCT00050843</DOC>
	<brief_summary>The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).</brief_summary>
	<brief_title>A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Eligible patients must have a diagnosis of myelodysplastic syndrome Life expectancy of at least 6 months. Patients must be able to adhere to the study visit schedule and other protocol requirements. Patients must understand and voluntarily sign an informed consent document. Women of childbearing potential (WCBP) must agree to practice abstinence or to use TWO methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment. Males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2004</verification_date>
</DOC>